FOXM1 and glioblastoma: Patients in the group with lower expression of FOXM1 after neoBev tended to show better OS than those with higher expression of FOXM1, suggesting that FOXM1 as a marker of proliferating GSCs may be a predictive factor for long-term survival during Bev therapy for newly diagnosed GBM.